OPRX241220P22500
- 0.00
- 0.000.00%
OptimizeRx Newsroom
Even With A 30% Surge, Cautious Investors Are Not Rewarding OptimizeRx Corporation's (NASDAQ:OPRX) Performance Completely
OptimizeRx to Participate in Upcoming Investor Conferences
OptimizeRx Corporation (NASDAQ:OPRX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
12 Health Care Stocks Moving In Thursday's Pre-Market Session
OptimizeRx | 10-Q: Q3 2024 Earnings Report
OptimizeRx Shares Slump After 3Q Results Miss Estimates, Cuts Outlook
OptimizeRx Price Target Lowered to $11 From $15 at Lake Street
Stifel Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $8
Roth MKM Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $16
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), Ontrak (OTRK) and Ayr Wellness (OtherAYRWF)
OptimizeRx Is Maintained at Market Outperform by JMP Securities
RBC Capital Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $7
OptimizeRx Analyst Ratings
Barclays Sticks to Their Hold Rating for OptimizeRx (OPRX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: PTC Therapeutics (PTCT), Medtronic (MDT) and OptimizeRx (OPRX)
JMP Securities Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $8
OptimizeRx: Buy Rating Affirmed Amid Financial Efficiency and Business Model Shift
Express News | OptimizeRx Corp : RBC Cuts Target Price to $7 From $14
OptimizeRx Corporation (OPRX) Q3 2024 Earnings Call Transcript Summary
OptimizeRx Corp. (OPRX) Surpasses Q3 Earnings Estimates